345 related articles for article (PubMed ID: 36185230)
1. FAIM2 is a potential pan-cancer biomarker for prognosis and immune infiltration.
Cai J; Ye Z; Hu Y; Wang Y; Ye L; Gao L; Sun Q; Tong S; Sun Z; Yang J; Chen Q
Front Oncol; 2022; 12():998336. PubMed ID: 36185230
[TBL] [Abstract][Full Text] [Related]
2. A pan-cancer analysis to determine the prognostic analysis and immune infiltration of HSPA5.
Zhu RK; Zhang W; Zhang YX; Hui Z; Wang XW
Curr Cancer Drug Targets; 2023 May; ():. PubMed ID: 37157205
[TBL] [Abstract][Full Text] [Related]
3. Systematic pan-cancer analysis of the potential tumor diagnosis and prognosis biomarker P4HA3.
Wu Y; Zhang B; Nong J; Rodrìguez RA; Guo W; Liu Y; Zhao S; Wei R
Front Genet; 2023; 14():1045061. PubMed ID: 37035741
[No Abstract] [Full Text] [Related]
4. Pan-cancer analyses of clinical prognosis, immune infiltration, and immunotherapy efficacy for TRPV family using multi-omics data.
Shen C; Fu C; Suo Y; Li K; Zhang Z; Yang S; Zhang Y; Lin Y; Li Z; Wu Z; Huang S; Chen H; Fan Z; Hu H
Heliyon; 2023 Jun; 9(6):e16897. PubMed ID: 37346342
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer analysis of Homeobox B9 as a predictor for prognosis and immunotherapy in human tumors.
Jin Q; Xu L; Wang J; Lin J; Lin H
Aging (Albany NY); 2023 Jun; 15(11):5096-5124. PubMed ID: 37301547
[TBL] [Abstract][Full Text] [Related]
6. SERPINH1 is a Potential Prognostic Biomarker and Correlated With Immune Infiltration: A Pan-Cancer Analysis.
Wang Y; Gu W; Wen W; Zhang X
Front Genet; 2021; 12():756094. PubMed ID: 35058967
[No Abstract] [Full Text] [Related]
7. NALCN is a potential biomarker and therapeutic target in human cancers.
He J; Xu J; Chang Z; Yan J; Zhang L; Qin Y
Front Genet; 2023; 14():1164707. PubMed ID: 37152978
[No Abstract] [Full Text] [Related]
8. A prognostic and immunological analysis of 7B-containing Kelch structural domain (KLHDC7B) in pan-cancer: a potential target for immunotherapy and survival.
Ding J; Ji X; Liu L; Chen DZ; Luo N; Yu XT; Guo F
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7857-7876. PubMed ID: 37039902
[TBL] [Abstract][Full Text] [Related]
9. Immune Infiltration of MMP14 in Pan Cancer and Its Prognostic Effect on Tumors.
Li M; Li S; Zhou L; Yang L; Wu X; Tang B; Xie S; Fang L; Zheng S; Hong T
Front Oncol; 2021; 11():717606. PubMed ID: 34604053
[TBL] [Abstract][Full Text] [Related]
10. YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.
Hu J; Qiu D; Yu A; Hu J; Deng H; Li H; Yi Z; Chen J; Zu X
Front Oncol; 2021; 11():607224. PubMed ID: 34026603
[TBL] [Abstract][Full Text] [Related]
11. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
12. Pan-Cancer and Single-Cell Analysis Reveals CENPL as a Cancer Prognosis and Immune Infiltration-Related Biomarker.
Feng Z; Chen Y; Cai C; Tan J; Liu P; Chen Y; Shen H; Zeng S; Han Y
Front Immunol; 2022; 13():916594. PubMed ID: 35844598
[TBL] [Abstract][Full Text] [Related]
13. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy.
Jia Y; Guo B; Zhang W; Wang F; Zhang Y; Zhang Q; Li E
Front Oncol; 2023; 13():1110207. PubMed ID: 37427102
[TBL] [Abstract][Full Text] [Related]
14. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
[TBL] [Abstract][Full Text] [Related]
15. Pan-Cancer Analysis of FURIN as a Potential Prognostic and Immunological Biomarker.
Zhou B; Gao S
Front Mol Biosci; 2021; 8():648402. PubMed ID: 33968987
[TBL] [Abstract][Full Text] [Related]
16. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer evidence of prognosis, immune infiltration, and immunotherapy efficacy for annexin family using multi-omics data.
Shen C; Zhang S; Zhang Z; Yang S; Zhang Y; Lin Y; Fu C; Li Z; Wu Z; Wang Z; Li Z; Guo J; Li P; Hu H
Funct Integr Genomics; 2023 Jun; 23(3):211. PubMed ID: 37358720
[TBL] [Abstract][Full Text] [Related]
18. Pan-Cancer Analysis of the N6-Methyladenosine Eraser FTO as a Potential Prognostic and Immunological Biomarker.
Zhao C; Liu Y; Ju S; Wang X
Int J Gen Med; 2021; 14():7411-7422. PubMed ID: 34744452
[TBL] [Abstract][Full Text] [Related]
19. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
20. A Pan-Cancer Analysis of the Oncogenic Role of
Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
Front Genet; 2022; 13():906174. PubMed ID: 35910232
[No Abstract] [Full Text] [Related]
[Next] [New Search]
